PANOVA: a pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Rivera
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors F. Rivera1, J. Gallego2, C. Guillén-Ponce3, M. Benavides4, J. Lopez-Martin5, M. Kueng6
  • 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 2Hospital General Universitario de Elche, Elche, Spain, /
  • 3H. Universitario Ramón y Cajal, IRYCIS, Madrid, Spain, /
  • 4Hospital Regional Universitario Carlos Haya, Málaga, Spain, /
  • 5Hospital 12 de Octubre, Madrid, Spain, /
  • 6Hôpital Fribourgeois, Fribourg, Switzerland, /


TTFields are alternating electric fields delivered to the region of the tumor by means of non-invasive transducer arrays surrounding the abdominal region. TTFields have an anti-mitotic effect by interfering with mitotic spindle formation, leading to apoptosis. In pancreatic cancer, TTFields decreased proliferation and clonogenic potential in vitro, and reduced tumor volume in vivo. The PANOVA trial is the first study testing TTFields in pancreatic cancer patients.